Perseverance, Personnel Change Helped Epix Win Its Vasovist Appeal To FDA
Executive Summary
After a long battle appealing "approvable" letters, Epix now appears to have a clear path to approval for Vasovist (gadofosveset)
You may also be interested in...
NDA Appeals Successful 31% Of Time Under CDER’s Formal Dispute Resolution
Product sponsors are successful almost one third of the time when they enter into the formal dispute resolution process with CDER regarding their applications
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
King's CorVu Gets Reluctant "No" From Advisory Committee
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.